

## SUPPLEMENTAL MATERIAL


**Table S1.** Agreement between sample collection sites and visits in males for type-specific HPV positivity, overall and by subgenus.<sup>a</sup>

	Penile and Scrotal Samples at Baseline					Penile and Scrotal Samples at Follow-up					Baseline and Follow-up: Combined Genital Site(s)				
	--	-+	+-	++	Kappa <sup>b</sup>	--	-+	+-	++	Kappa <sup>b</sup>	--	-+	+-	++	Kappa <sup>b</sup>
<b>Male 1</b>															
<b>Overall</b>	591	5	15	37	0.77	712	6	18	20	0.61	1154	18	27	61	0.71
<b>Subgenus 1</b>	98	1	3	6	0.73	116	1	5	4	0.55	190	3	6	11	0.69
<b>Subgenus 2</b>	362	1	11	22	0.77	435	4	13	10	0.52	706	12	15	37	0.71
<b>Subgenus 3</b>	131	3	1	9	0.80	161	1	0	6	0.92	258	3	6	13	0.73
<b>Male 2</b>															
<b>Overall</b>	497	4	22	17	0.54	168	1	2	9	0.85	999	37	26	54	0.60
<b>Subgenus 1</b>	82	0	4	4	0.65	29	0	0	1	1.00	164	4	4	14	0.75
<b>Subgenus 2</b>	303	3	15	9	0.47	100	1	2	7	0.81	609	25	17	31	0.56
<b>Subgenus 3</b>	112	1	3	4	0.65	39	0	0	1	1.00	226	8	5	9	0.55

Abbreviation: HPV, human papillomavirus.


<sup>a</sup> Subgenus 1 includes low oncogenic risk mucosal HPVs 6, 11, 40, 42, 44, and 54; subgenus 2 includes high oncogenic risk mucosal HPVs 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 69, 70, 73 and 82; and subgenus 3 includes commensal mucocutaneous HPVs 61, 62, 71, 72, 81, 83, 84 and 89 [18, 19].

<sup>b</sup> Kappa values 0.41-0.60 indicate moderate, 0.61-0.80 substantial, and 0.81-1.00 almost perfect agreement [17].



**Figure S1.** Distribution of time elapsed between male 1 last available sample and male 2 baseline sample within linked partnerships.

**Figure S1 Legend:** While all male 2 provided a baseline genital sample, male 1 follow-up visits did not begin until October 2006. As such, we measured the time between available male 1 and male 2 genital samples based on the final sample male 1 provided. When male 1 provided a follow-up sample, we measured the time between male 1 follow-up and male 2 baseline; otherwise, we measured the time between male 1 baseline and male 2 baseline.



**Figure S2.** Type-specific expected human papillomavirus (HPV) concordance between males 1 and 2.

**Figure S2 Legend:** Distribution of expected concordance for 36 individual HPV types. Assuming the HPV positivity of males 1 and 2 is independent, the number of infections for which males 1 and 2 are expected to be concordant is equal to the product of the infection prevalence, divided by the total detectable infections (i.e.,  $\frac{P_{HPVx, Male1} \times P_{HPVx, Male2}}{T_{HPVx}}$ ).